EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY 4.0

B cells and the therapeutic index of checkpoint blockade

Chuan-Yuan Li

Journal of Clinical Investigation · 02.11.2026 · 136 (21)

DOI: 10.1172/jci212237 ↗

Kurz gefasst

Kommentar in der Zeitschrift Journal of Clinical Investigation, online erschienen am 02.11.2026. Verfasst von Chuan-Yuan Li. Beteiligte Einrichtung: Chinese Institute for Molecular and Cellular Therapeutics, Chinese Institutes for Medical Research, Beijing, China. Hauptthemen laut MEDLINE: Melanoma, B-Lymphocytes, Immune Checkpoint Inhibitors. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combined CTLA-4 and PD-1 blockade is effective in treating melanoma and additional cancers but frequently causes immune-related adverse events (irAEs). irAEs cause treatment disruption and discontinuation and remain difficult to manage clinically. In this issue, Dhodapkar and colleagues assessed data from a small randomized clinical trial testing rituximab-mediated B cell depletion in combined CTLA-4/PD-1 blockade–treated patients with advanced melanoma. Despite premature discontinuation of the trial due to a high rate of rituximab hypersensitivity, they report that preemptive B cell depletion was associated with fewer severe toxicities without evident loss of antitumor activity. These findings raise broader questions about the organization of checkpoint-induced autoimmunity, the emerging concept of immune reset, and the compartment-specific roles of B cells in antitumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaB-LymphocytesImmune Checkpoint InhibitorsHumansCTLA-4 AntigenProgrammed Cell Death 1 ReceptorRituximabAnimals

Substanzen

CTLA-4 AntigenProgrammed Cell Death 1 ReceptorRituximabCTLA4 protein, humanPDCD1 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Chinese Institute for Molecular and Cellular Therapeutics, Chinese Institutes for Medical Research, Beijing, China.
  • School of Basic Medical Sciences, Capital Medical University, Beijing, China.

Zitieren

APA

Li, C. Y. (2026). B cells and the therapeutic index of checkpoint blockade. Journal of Clinical Investigation, 136(21). https://doi.org/10.1172/jci212237

Vancouver

Li CY. B cells and the therapeutic index of checkpoint blockade. Journal of Clinical Investigation. 2026;136(21). doi:10.1172/jci212237

BibTeX
@article{Li2026,
  author = {Li, Chuan-Yuan},
  title = {B cells and the therapeutic index of checkpoint blockade},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {21},
  doi = {10.1172/jci212237}
}
Kostenlos starten →